Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Intel’s Rollercoaster: A Deceptive Rally Meets Harsh Reality

Dieter Jaworski by Dieter Jaworski
November 7, 2025
in Earnings, Nasdaq, Semiconductors
0
Intel Stock
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Intel’s recent quarterly earnings initially sparked a wave of investor enthusiasm, propelling its shares to a record peak. This jubilation, however, was brutally short-lived. The stock experienced a dramatic reversal, shedding over ten percent of its value in a swift downturn that has placed the semiconductor titan under significant pressure. The critical question emerges: were the seemingly robust figures merely a facade?

The Illusion of Profitability

A deeper analysis of the third-quarter report reveals the source of investor anxiety. While Intel posted a net profit exceeding $4 billion, this impressive result was primarily fueled by a one-time, non-recurring gain of $5.5 billion from the sale of its majority stake in the Altera division. Beneath this surface, the company’s core operational performance showed a more modest improvement, turning to a profit of $683 million from a loss in the prior-year period.

The persistent weak spot remains Intel’s critical foundry business, the unit responsible for chip manufacturing, which continues to operate at a substantial loss. This fundamental issue casts a long shadow over the company’s recovery narrative.

A Meteoric Ascent and Precipitous Drop

On the surface, Intel’s Q3 results appeared strong. The company reported revenue of $13.7 billion, a three percent year-over-year increase that surpassed market forecasts. Adjusted earnings per share came in at $0.23, soundly beating analyst predictions. The immediate market reaction was a powerful surge, driving the share price beyond the $42 mark.

This rally, however, hit a formidable wall of resistance. Almost immediately after touching its new high, the stock faced a severe sell-off. In a single Thursday session, Intel shares fell three percent, sliding to approximately $37. The previously established upward trend was decisively broken, replaced by a clear and concerning downward trajectory.

Should investors sell immediately? Or is it worth buying Intel?

A Sobering Forecast Dampens Spirits

Compounding these concerns is Intel’s own guidance for the current quarter. The company anticipates revenue in the range of $12.8 to $13.8 billion. More alarmingly, it projects an adjusted profit of just $0.08 per share. This outlook signals a sharp decline compared to the same period last year and serves as a cold shower for any investors betting on a sustained turnaround.

Financial Lifelines Fail to Buoy Confidence

Intel has actively taken steps to stabilize its financial position through several strategic capital injections:

  • $5.7 billion in U.S. CHIPS Act government funding
  • A $5.0 billion strategic investment from NVIDIA
  • $2.0 billion from SoftBank through a new share issuance

These measures have successfully enhanced the company’s liquidity and facilitated debt reduction, making the balance sheet appear healthier. Despite this, market analysts remain largely unconvinced. The consensus rating for Intel stock currently sits at “Reduce” or “Hold.” While a small number of firms have raised their price targets, the average objective remains below the stock’s recent highs. The prevailing expert advice is to either hold or sell.

Intel now stands at a critical juncture. Without demonstrable and convincing operational improvements—most critically within its foundry division—the company is likely to continue facing strong headwinds.

Ad

Intel Stock: Buy or Sell?! New Intel Analysis from February 8 delivers the answer:

The latest Intel figures speak for themselves: Urgent action needed for Intel investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Intel: Buy or sell? Read more here...

Tags: Intel
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Ocugen Stock

Ocugen's Financial Health Sparks Investor Concern Amid Aggressive R&D Push

Procter & Gamble Stock

Procter & Gamble Shares: A Market Conundrum Amid Strong Fundamentals

Hims & Hers Stock

Hims & Hers Shares Tumble as Profit Miss Overshadows Revenue Growth

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com